欢迎莅临·太阳集团-www.tcy8722.com-Brand Company

On March 30, 2026, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™, SSE: 688016) announced the annual results of Endovastec™ and its subsidiaries (the Company) for the year ended December 31, 2025 (the Reporting Period). During the Reporting Period, the Company recorded revenue of RMB 1.351 billion, with a net profit attributable to shareholders of listed companies of RMB 563 million and basic earnings per share of RMB 4.65. The total amount of cash dividends and share repurchases is expected to reach RMB 398 million (including interim cash dividends already distributed), representing a cash dividend of RMB 23 per 10 shares (tax inclusive).

The Company continued to advance its dual strategic of innovation-driven growth and global expansion, maintaining steady and positive business performance.

Commitment to Innovation: Building More Competitive Total Solutions

The Company remains focused on technological innovation, advancing product development and clinical translation across aortic, peripheral vascular, and tumor intervention fields, further enhancing its total disease solutions. Since 2025, multiple key pipeline products have achieved significant progress in China.

In the field of aortic intervention, key products including Cratos™ Branched Aortic Stent Graft System(Cratos™) and Bi-modular Minos™ Abdominal Aortic Stent Graft and Delivery System received marketing approval from the National Medical Products Administration (NMPA) of China, while Hector™ Multi-Branch Thoracic Stent Graft System(Hector™) has been approved for the NMPA’s Special Review Procedures for Innovative Medical Devices (“Green Path”) and has initiated pre-market clinical trials, Zelus™ Thoracoabdominal Aortic Stent Graft System(Zelus™) has obtained a custom-made device filing certificate, Aegis™ II Abdominal Aortic Stent Graft System is currently under registration review in China, and the Iliac Branched Stent Graft System is expected to enter pre-market clinical trials.

In the field of peripheral arterial intervention, HawkMaster™ Detachable Fibered Embolization Coils received NMPA’s marketing approval, SunRiver™ BTK Drug-Coated Balloon Catheter and SunFlow™ Drug-Eluting Peripheral Vascular Stent System are currently under registration review and in pre-market clinical trials, respectively. HawkNest™ Fibered Embolization Coils has progressed well in post-market clinical use.

In the peripheral venous intervention field, Fishhawk™ Mechanical Thrombectomy Catheter (recognized by NMPA as an Innovative Medical Device) and SeaNet™ Embolic Protection Device are currently under registration review in China. Vflower™ Venous Stent System (recognized by NMPA as an Innovative Medical Device), SeaDragon™ PTA Balloon Dilatation Catheter, Vewatch™ Vena Cava Filter, and Vepack™ Snare Retrieval Kit have all been advancing smoothly in post-market clinical use.

In the field of tumor intervention, FinderSphere™ Polyvinyl Alcohol Embolic Microspheres and Tipspear™ Transjugular Liver Access Set received NMPA’s marketing approval. HepaFlow™ TIPS Stent Graft System (recognized by NMPA as an Innovative Medical Device), FluentSphere™ Polyvinyl Alcohol Embolic Microspheres, and TorqueFlex™ Microcatheters are currently under registration review.

At present, the Company has a total of 33 marketed products worldwide, including 6 with CE certification and 3 with EU custom-made device certificates. Among its products already launched and under development, 9 have been approved for the NMPA’s “Green Path”, representing a leading position in the industry.

Accelerating Global Expansion: Increasing Contribution from Markets outside China

The Company continues to execute its globalization strategy with determination, strengthening its market presence in China while accelerating Global expansion.

During the Reporting Period, revenue from markets outside China increased by more than 56% year-over-year, with its contribution to total revenue further rising to over 19% . The Company has obtained more than 110 product registrations outside China and expanded its presence to nearly 50 countries and regions across Europe, Latin America, Asia, and Africa.

Since 2025, the Company’s key innovative products have continued to make notable breakthroughs in international markets. Hector™ obtained an EU custom-made device certificate, achieved multiple commercial applications, and was granted the U.S. FDA Breakthrough Device Designation in February 2026. Cratos™ has completed the submission of its CE certification application and has been used commercially as a custom-made device. Talos™ Thoracic Stent Graft System obtained CE MDR certification and has been clinically used in multiple countries in Latin America and Southeast Asia. Castor™ Branched Aortic Stent Graft System completed its first implantation in Singapore of its fenestrated variant. Zelus™ has submitted its application for an EU custom-made device certificate and has completed its first clinical use globally.

In addition, 2025 marked the first full year following the acquisition of Lombard Medical. Through effective integration, Lombard achieved profitability, demonstrating the value of the acquisition and the Company’s global operational capabilities.

Commitment to High-Quality Development and Corporate Social Responsibility

The Company remains committed to high-quality and sustainable development, consistently receiving “A” ratings and above from multiple ESG rating agencies in China. It has published its CSR Reports for six consecutive years and has run the “Endovastec Public Welfare Action” Relief Program for impoverished patients with aortic diseases for four consecutive years, benefiting over 140 patients to date.

Since 2025, the Company has received multiple national-level awards and  recognitions in China for its achievements in technological innovation and industrial contribution, advancing technological progress and clinical application in the treatment of aortic and peripheral vascular diseases, including the China Patent Gold Award for Castor™ Branched Aortic Stent Graft System, the Second Prize of the 2024 Beijing Science and Technology Progress Award, the First Prize of the 2025 Hubei Science and Technology Progress Award，Shanghai Brand Leadership Benchmark Enterprise and Pudong New Area’s First Corporate Headquarters for Global Expansion.

“In 2025, we delivered solid growth despite a dynamic global market environment, with continued progress in global expansion, product portfolio, and market coverage. I would like to sincerely thank our employees, customers, partners, shareholders, and the broader community for their continued trust and support. Looking ahead, we will remain focused on advancing total solutions for aortic, peripheral vascular, and tumor diseases, while accelerating our global expansion. Adhering to the mission of providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, we are committed to building a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine,” said Qing Zhu, PhD, President of Endovastec™.